• Something wrong with this record ?

The histamine H4 receptor is a potent inhibitor of adhesion-dependent degranulation in human neutrophils

K. Dib, T. Perecko, V. Jenei, C. McFarlane, D. Comer, V. Brown, M. Katebe, T. Scheithauer, RL. Thurmond, PL. Chazot, M. Ennis,

. 2014 ; 96 (3) : 411-8.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15014331

The histamine H4 receptor regulates the inflammatory response. However, it is not known whether this receptor has a functional role in human neutrophils. We found that fMLP (1 μM), but not histamine (0.1-1 μM), induced Mac-1-dependent adhesion, polarization, and degranulation (release of lactoferrin). A pretreatment of neutrophils with histamine (0.001-1 μM) or JNJ 28610244 (0.1-10 μM), a specific H4 receptor agonist, led to inhibition of degranulation. Total inhibition of degranulation was obtained with 0.1 μM histamine and 10 μM JNJ 28610244. Furthermore, such inhibition by histamine of degranulation was reversed by JNJ 7777120 and JNJ 28307474, two selective H4 receptor antagonists. However, neither histamine nor the H4 receptor agonist JNJ 28610244 prevented fMLP-induced, Mac-1-dependent adhesion, indicating that the H4 receptor may block signals emanating from Mac-1-controlling degranulation. Likewise, engagement of the H4 receptor by the selective agonist JNJ 28610244 blocked Mac-1-dependent activation of p38 MAPK, the kinase that controls neutrophil degranulation. We also show expression of the H4 receptor at the mRNA level in ultrapure human neutrophils and myeloid leukemia PLB-985 cells. We concluded that engagement of this receptor by selective H4 receptor agonists may represent a good, therapeutic approach to accelerate resolution of inflammation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014331
003      
CZ-PrNML
005      
20150428101026.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1189/jlb.2AB0813-432RR $2 doi
035    __
$a (PubMed)24799603
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dib, Karim $u Centre for Infection and Immunity, Queen's University of Belfast, Northern Ireland, United Kingdom; k.dib@qub.ac.uk.
245    14
$a The histamine H4 receptor is a potent inhibitor of adhesion-dependent degranulation in human neutrophils / $c K. Dib, T. Perecko, V. Jenei, C. McFarlane, D. Comer, V. Brown, M. Katebe, T. Scheithauer, RL. Thurmond, PL. Chazot, M. Ennis,
520    9_
$a The histamine H4 receptor regulates the inflammatory response. However, it is not known whether this receptor has a functional role in human neutrophils. We found that fMLP (1 μM), but not histamine (0.1-1 μM), induced Mac-1-dependent adhesion, polarization, and degranulation (release of lactoferrin). A pretreatment of neutrophils with histamine (0.001-1 μM) or JNJ 28610244 (0.1-10 μM), a specific H4 receptor agonist, led to inhibition of degranulation. Total inhibition of degranulation was obtained with 0.1 μM histamine and 10 μM JNJ 28610244. Furthermore, such inhibition by histamine of degranulation was reversed by JNJ 7777120 and JNJ 28307474, two selective H4 receptor antagonists. However, neither histamine nor the H4 receptor agonist JNJ 28610244 prevented fMLP-induced, Mac-1-dependent adhesion, indicating that the H4 receptor may block signals emanating from Mac-1-controlling degranulation. Likewise, engagement of the H4 receptor by the selective agonist JNJ 28610244 blocked Mac-1-dependent activation of p38 MAPK, the kinase that controls neutrophil degranulation. We also show expression of the H4 receptor at the mRNA level in ultrapure human neutrophils and myeloid leukemia PLB-985 cells. We concluded that engagement of this receptor by selective H4 receptor agonists may represent a good, therapeutic approach to accelerate resolution of inflammation.
650    _2
$a buněčná adheze $x účinky léků $x fyziologie $7 D002448
650    12
$a degranulace buněk $x účinky léků $7 D015550
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a tvar buňky $x účinky léků $7 D048430
650    _2
$a kultivované buňky $7 D002478
650    _2
$a cytochalasin B $x farmakologie $7 D003571
650    _2
$a fibrinogen $7 D005340
650    _2
$a histamin $x farmakologie $7 D006632
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x farmakologie $7 D007211
650    _2
$a akutní promyelocytární leukemie $x patologie $7 D015473
650    _2
$a antigen-1 spojený s lymfocytární funkcí $x chemie $7 D016169
650    _2
$a MAP kinasový signální systém $x účinky léků $7 D020935
650    _2
$a makrofágový antigen 1 $x fyziologie $7 D016177
650    _2
$a N-formylmethionin-leucyl-fenylalanin $x farmakologie $7 D009240
650    _2
$a neutrofily $x účinky léků $x fyziologie $7 D009504
650    _2
$a oximy $x farmakologie $7 D010091
650    _2
$a piperaziny $x farmakologie $7 D010879
650    _2
$a piperidiny $x farmakologie $7 D010880
650    _2
$a konformace proteinů $x účinky léků $7 D011487
650    _2
$a pyridiny $x farmakologie $7 D011725
650    _2
$a messenger RNA $x biosyntéza $x genetika $7 D012333
650    _2
$a receptory spřažené s G-proteiny $x agonisté $x antagonisté a inhibitory $x fyziologie $7 D043562
650    _2
$a receptory histaminu $x fyziologie $7 D011968
650    _2
$a mitogenem aktivované proteinkinasy p38 $x fyziologie $7 D048051
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Perecko, Tomas $u Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences, Bratislava, Slovakia; Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic;
700    1_
$a Jenei, Veronika $u Cancer Sciences Unit, University of Southampton, United Kingdom;
700    1_
$a McFarlane, Cheryl $u Centre for Infection and Immunity, Queen's University of Belfast, Northern Ireland, United Kingdom;
700    1_
$a Comer, David $u Centre for Infection and Immunity, Queen's University of Belfast, Northern Ireland, United Kingdom;
700    1_
$a Brown, Vanessa $u Centre for Infection and Immunity, Queen's University of Belfast, Northern Ireland, United Kingdom;
700    1_
$a Katebe, Mwape $u School of Biological and Biomedical Sciences, Durham University, United Kingdom; and.
700    1_
$a Scheithauer, Torsten $u Centre for Infection and Immunity, Queen's University of Belfast, Northern Ireland, United Kingdom;
700    1_
$a Thurmond, Robin L $u Janssen Research and Development, San Diego, California, USA.
700    1_
$a Chazot, Paul L $u School of Biological and Biomedical Sciences, Durham University, United Kingdom; and.
700    1_
$a Ennis, Madeleine $u Centre for Infection and Immunity, Queen's University of Belfast, Northern Ireland, United Kingdom;
773    0_
$w MED00002765 $t Journal of leukocyte biology $x 1938-3673 $g Roč. 96, č. 3 (2014), s. 411-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24799603 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150428101330 $b ABA008
999    __
$a ok $b bmc $g 1071912 $s 897209
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 96 $c 3 $d 411-8 $i 1938-3673 $m Journal of leukocyte biology $n J Leukoc Biol $x MED00002765
LZP    __
$a Pubmed-20150420

Find record

Citation metrics

Archiving options